L. Pierre, M. Philippe, M. Pharmacie-galénique-alain, M. Chimie-thérapeutique-patrick, M. Jean-louis et al., Chimie physique générale, Biochimie, Biologie moléculaire Jean-Michel SIMON ............................. Economie de la santé

B. Sandrine, B. Mariette, B. Biologie-cellulaire-emmanuelle, . Communication, B. Santé-isabelle et al., Chimie thérapeutique Chimie thérapeutique

B. Ariane, B. Cédric, C. Jean-claude, C. Chimie-générale-et-minérale-igor, C. Chimie-analytique-joël et al., Chimie thérapeutique, Microbiologie clinique Béatrice FAIVRE ??????????????..Hématologie -Génie Biologique

J. Olivier, . Toxicologie, K. Sécurité-sanitaire-francine, L. Pharmacie-galénique-alexandrine, B. Informatique et al., Chimie organique Biophysique

S. Anne, S. Pharmacie-galénique-marie-paule, B. Mycologie, T. Nathalie, T. Santé-publique-gabriel et al., Pharmacie galénique PROFESSEUR ASSOCIE, Biochimie et Biologie

L. Facteurs-de-croissance-plaquettaire?????????????, 77 3.3.1. La première génération de facteurs de croissance plaquettaire, p.77

M. Aapro, D. Cameron, R. Pettengell, J. Bohlius, and J. Crawford, EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours, European Journal of Cancer, vol.42, issue.15, pp.2433-53, 2006.
DOI : 10.1016/j.ejca.2006.05.002

N. Afdhal, E. Giannini, G. Tayyab, A. Mohsin, and J. Lee, Eltrombopag in chronic liver disease patients with thrombocytopenia undergoing a elective invasive procedure: results from elevate, a randomized clinical trial

A. Aharon and B. Brenner, Microparticles, thrombosis and cancer. Best practice &research clinical haematology, 22, pp.61-69, 2009.
DOI : 10.1016/j.beha.2008.11.002

M. Auerbach, H. Ballard, and J. Glaspy, Clinical update: intravenous iron for anaemia, The Lancet, vol.369, issue.9572, pp.1502-1504, 2007.
DOI : 10.1016/S0140-6736(07)60689-8

M. Auerbach, H. Ballard, and J. Trout, Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial, Journal of Clinical Oncology, vol.22, issue.7, pp.1301-1307
DOI : 10.1200/JCO.2004.08.119

E. Azoulay and C. Delclaux, Toxicit?? pulmonaire du G-CSF??: Revue syst??matique de la litt??rature clinique et exp??rimentale1G-CSF related pulmonary toxicity, R??animation, vol.11, issue.5, pp.326-332
DOI : 10.1016/S1624-0693(02)00252-9

C. Beaumont, Actualités du métabolisme du fer Revue de médecine interne, pp.307-310

Y. Beuzard, News in brief, Hématologie, vol.7, issue.5, 2001.

O. Beyne-rauzy, An??mie inflammatoire??: physiopathologie et prise en charge, La Revue de M??decine Interne, vol.30
DOI : 10.1016/j.revmed.2009.09.013

J. Blom, S. Osanto, and F. Rosendaal, The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma, Journal of Thrombosis and Haemostasis, vol.18, issue.10, pp.1760-1765, 2004.
DOI : 10.1097/00005792-199909000-00001

J. Bohlius, K. Schmidlin, G. Schwarzer, S. Trelle, J. Seidenfeld et al., Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: meta-analysis of randomized trials, Lancet, pp.373-1532, 2009.

D. Brizel, G. Sibley, L. Prosnitz, L. Scher, and M. Dewhirst, Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck, International Journal of Radiation Oncology*Biology*Physics, vol.38, issue.2, pp.285-289, 1997.
DOI : 10.1016/S0360-3016(97)00101-6

H. Büller, G. Agnelli, R. Hull, T. Hyers, M. Prins et al., Antithrombotic Therapy for Venous Thromboembolic Disease, Chest, vol.126, issue.3, pp.401-428, 2004.
DOI : 10.1378/chest.126.3_suppl.401S

J. Bussel, D. Kuter, J. George, L. Aledort, and A. Lichtin, Long-term dosing of AMG531 is effective and well tolerated in thrombocytopenic patients with immune thrombocytopenic purpura, Blood, vol.106, p.220, 2005.

J. Bussel, D. Provan, T. Shamsi, G. Cheng, and B. Psaila, Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial, The Lancet, vol.373, issue.9664, pp.641-648, 2009.
DOI : 10.1016/S0140-6736(09)60402-5

A. Byrne, D. Bouchier-hayes, and J. Harmey, Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF), Journal of Cellular and Molecular Medicine, vol.8, issue.4, pp.777-794, 2005.
DOI : 10.1073/pnas.2135406100

P. Carde, inhibiteurs de l'érythropoïèse: de la physiologie à la thérapeutique, Bull. Acad . Natle. Méd, vol.178, pp.793-806, 1994.

A. Carobbio, G. Finazzi, E. Antonioli, P. Guglielmelli, A. Vannucchi et al., Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia, Blood, vol.112, issue.8, pp.3135-3137, 2008.
DOI : 10.1182/blood-2008-04-153783

B. Clavo, N. Santana, and A. Biete, Epoetin and mortality in patients with cancer. The Lancet, p.287, 2009.

E. Cortesi, A. Mancuso, L. Moscetti, R. Saltarelli, and M. Palma, High incidence of thrombosis using G-CSF in the treatment of chemotherapy-induced neutropenia, European Journal of Cancer, vol.37, issue.6, p.100, 2001.
DOI : 10.1016/S0959-8049(01)80853-4

E. Cramer-bordé and . Production-plaquettaire, Régulation cellulaire et moléculaire. EMC Hématologie, pp.13-019, 2008.

N. Dahl, D. Henry, and D. Coyne, Thrombosis with erythropoiesis stimulating agents does iron-deficient erythropoiesis play a role? Seminars in Dialysis, pp.210-211, 2008.

A. Delluc, L. Bressollette, B. Guias, K. Lacut, C. Delluc et al., Prévalence et localisation des cancers lors du diagnostic de thrombose veineuse profonde symptomatique des membres inférieurs. La revue de Médecine interne, pp.25-26, 2008.

R. Descourt, M. Righini, M. Carrier, L. Gal, and G. , Place du cancer parmi les facteurs de risque de la maladie thromboembolique veineuse, Pathologie Biologie, vol.56, issue.4, pp.178-183, 2008.
DOI : 10.1016/j.patbio.2007.12.008

S. Dische, Radiotherapy and anaemia ??? the clinical experience, Radiotherapy and Oncology, vol.20, pp.35-40, 1991.
DOI : 10.1016/0167-8140(91)90184-I

J. Donadieu and O. Fenneteau, Neutrop??nies constitutionnelles et acquises, EMC - H??matologie, vol.2, issue.3, pp.158-186, 2005.
DOI : 10.1016/j.emch.2005.07.002

J. Donadieu and O. Fenneteau, Neutrop??nies constitutionnelles et acquises, EMC - H??matologie, vol.2, issue.3, pp.158-186, 2005.
DOI : 10.1016/j.emch.2005.07.002

I. Elalamy, E. Verdy, G. Gerotziafas, and M. Hatmi, Physiopathog??nie de la maladie thromboembolique veineuse au cours du cancer, Pathologie Biologie, vol.56, issue.4, pp.184-194, 2008.
DOI : 10.1016/j.patbio.2008.03.003

J. Eschbach, Iron requirements in erythropoietin therapy, Best Practice & Research Clinical Haematology, vol.18, issue.2
DOI : 10.1016/j.beha.2004.09.005

D. Farge-bancel, L. Florea, L. Bosquet, and P. Debourdeau, Traitement de la maladie thromboembolique veineuse chez le canc??reux, Pathologie Biologie, vol.56, issue.4, pp.220-228, 2008.
DOI : 10.1016/j.patbio.2008.02.007

J. Fisher and E. , Erythropoietin: Physiologic and Pharmacologic Aspects, Experimental Biology and Medicine, vol.216, issue.3, pp.358-369, 1997.
DOI : 10.3181/00379727-216-44183

C. Fribourg and C. Denis, Plaquettes et tumeurs, Hématologie, vol.12, pp.400-411, 2006.

A. Fyles, M. Milosevic, R. Wong, M. Kavanagh, M. Pintilie et al., Oxygenation predicts radiation response and survival in patients with cervix cancer, Radiotherapy and Oncology, vol.48, issue.2, pp.149-156, 1998.
DOI : 10.1016/S0167-8140(98)00044-9

O. Gharbi, B. H. Hassen, S. Kaabia, N. Limam, S. et al., Les neutrop??nies f??briles chimio-induites??: ?? propos de 200??pisodes, Pathologie Biologie, vol.56, issue.3, pp.154-157, 2008.
DOI : 10.1016/j.patbio.2007.09.025

B. Godeau, Les agonistes du récepteur de la thrombopoïétine : vers une révolution du traitement du purpura thrombopénique immunologique ? La revue de medecine interne, pp.203-205, 2009.

M. Gougerot-pocidalo, Polynucléaires neutrophiles humains. Revue Francaise des Laboratoires, pp.43-51, 2002.
DOI : 10.1016/s0338-9898(02)80180-9

A. Greijer and E. Van-der-wall, The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis, Journal of Clinical Pathology, vol.57, issue.10
DOI : 10.1136/jcp.2003.015032

J. Heit, M. Silverstein, D. Mohr, T. Petterson, O. Fallon et al., Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism, Archives of Internal Medicine, vol.160, issue.6, pp.809-815, 2000.
DOI : 10.1001/archinte.160.6.809

C. Hennequin, Erythropoietin radiation therapy, Bull Cancer, vol.93, issue.5, pp.495-499, 2006.

M. Hockel, K. Schlenger, B. Aral, M. Mitze, U. Schaffer et al., Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, Cancer Res, vol.56, pp.4509-4515, 1996.

A. Houston, L. Stevens, and V. Cour, Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers, British Journal of Clinical Pharmacology, vol.59, issue.3, pp.279-284, 1999.
DOI : 10.1111/j.1600-0609.1997.tb00972.x

X. Huang, L. Pierce, G. Chen, K. Chang, G. Spangrude et al., Erythropoietin receptor signaling regulates both erythropoiesis and megakaryopoiesis in vivo, Blood Cells, Molecules, and Diseases, vol.44, issue.1, pp.1-6
DOI : 10.1016/j.bcmd.2009.09.007

W. Jelkmann, J. Bohlius, M. Hallek, and A. Sytkowski, The erythropoietin receptor in normal and cancer tissues, Critical Reviews in Oncology/Hematology, vol.67, issue.1
DOI : 10.1016/j.critrevonc.2008.03.006

H. Kantarjian, P. Fenaux, M. Sekeres, P. Becker, and A. Boruchov, Phase ½ study of AMG 531 in thrombocytopenic patients with low-risk myelodysplastic syndrome (MDS): update including extented treatment, Blood, 2007.

M. Karaoka, Y. Moriya, Y. Moriguchi, T. Iway, K. Fujimoto-ouchi et al., Effect of erythropoietin on human tumor growth in xenograft models, Molecular Medicine Reports, vol.2010, issue.3, pp.95-101

E. Katodritou, M. Dimopoulos, K. Zervas, and E. Terpos, Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma, Cancer Treatment Reviews, vol.35, issue.8, pp.738-743, 2009.
DOI : 10.1016/j.ctrv.2009.08.002

D. Kuter, J. Bussel, R. Lyons, V. Pullarkat, and T. Gernsheimer, Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial, The Lancet, vol.371, issue.9610, pp.395-403, 2008.
DOI : 10.1016/S0140-6736(08)60203-2

S. Lasocki, M. Garnier, L. Ley, A. Benbarra, C. Beaumont et al., La prescription martiale en réanimation aujourd'hui : une enquête de pratique. Annales Fr d'Anesthésie et de Réanimation, pp.909-914

G. Laval, N. Beziaud, M. Laramas, S. Courby, and J. Cahn, ??rythropo????tine (EPO) et an??mie en soins palliatifs chez le patient atteint de cancer, M??decine Palliative : Soins de Support - Accompagnement - ??thique, vol.6, issue.5, pp.274-284, 2007.
DOI : 10.1016/S1636-6522(07)92568-4

L. Fur, E. Albarghach, M. Pradier, and O. , Erythropoïétine et radiothérapie, Cancer Radiothérapie, vol.2009, pp.1-6, 2578.

C. Liongue, C. Wright, A. Russel, and A. Ward, Granulocyte colony-stimulating factor receptor: Stimulating granulopoiesis and much more, The International Journal of Biochemistry & Cell Biology, vol.41, issue.12, pp.2372-2375, 2009.
DOI : 10.1016/j.biocel.2009.08.011

S. Luo, K. Ogata, T. Kato, and K. Dan, Effect of Thrombopoietin on Proliferation of Blasts from Patients with Myelodysplastic Syndromes, Stem Cells, vol.84, issue.2, pp.112-119, 2000.
DOI : 10.1111/j.1365-2141.1982.tb08475.x

I. Mahé, A. Bosquet, A. Medjkane, C. Bal-dit-sollier, and L. Drouet, Surveillance des traitements anticoagulants chez les patients atteints de cancer, Pathologie Biologie, vol.56, issue.4, pp.239-244, 2008.
DOI : 10.1016/j.patbio.2008.02.011

I. Mahé, A. Bosquet, A. Medjkane, C. Bal-dit-sollier, and L. Drouet, Surveillance des traitements anticoagulants chez les patients atteints de cancer, Pathologie Biologie, vol.56, issue.4, pp.239-244, 2008.
DOI : 10.1016/j.patbio.2008.02.011

R. Mc-millian and C. Durette, Long-term outcomes in adults with chronic ITP after splenectomy failure, Blood, vol.104, issue.4, pp.956-960, 2004.
DOI : 10.1182/blood-2003-11-3908

J. Mchutchison, G. Dusheiko, M. Shiffman, M. Rodriguez-torres, and S. Sigal, Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C, New England Journal of Medicine, vol.357, issue.22, pp.2227-2236, 2007.
DOI : 10.1056/NEJMoa073255

M. Michel, Agoniste du récepteur de la thrombopoïétine : Actualités et perspectives

M. Milano and . Cancer, anémie et place de l'érythropoïétine, J Pharm Clin, vol.24, pp.11-16, 2005.

P. Mismetti, K. Rivron-guillot, and N. Moulin, Place des filtres caves dans le traitement de la maladie thromboembolique veineuse chez les patients canc??reux, Pathologie Biologie, vol.56, issue.4, pp.229-232, 2008.
DOI : 10.1016/j.patbio.2008.03.002

O. Morel, N. Morel, B. Hugel, L. Jesel, and S. Vinzio, Les microparticules circulantes??: r??les physiologiques et implications dans les maladies inflammatoires et thrombotiques, La Revue de M??decine Interne, vol.26, issue.10, pp.791-801, 2005.
DOI : 10.1016/j.revmed.2005.03.015

O. Morel, F. Toti, and J. Freyssinet, Marqueurs des pathologies thrombotiques, Annales Pharmaceutiques Fran??aises, vol.65, issue.2, pp.75-84, 2007.
DOI : 10.1016/S0003-4509(07)90020-6

D. Moro-sibilot, A. Toffart, G. Gereige, and M. Coudurier, Les facteurs de croissance h??matopo????tique en canc??rologie thoracique, Revue des Maladies Respiratoires Actualit??s, vol.1, issue.4, pp.314-319
DOI : 10.1016/S1877-1203(09)72500-5

L. Mulcahy, The erythropoietin receptor, Seminars in Oncology, vol.28, pp.19-23, 2001.
DOI : 10.1016/S0093-7754(01)90208-8

H. Nonoguchi, Y. Otaki, M. Tokuyama, S. Yamamoto, and T. Nakanishi, Epoetin and mortality in patients with cancer. The Lancet, pp.9686-287, 2009.

M. Nordsmark, M. Overgaard, and J. Overgaard, Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck, Radiotherapy and Oncology, vol.41, issue.1, pp.31-39, 1996.
DOI : 10.1016/S0167-8140(96)91811-3

M. Pavic, P. Debourdeau, M. Aletti, D. Farge-bancel, and H. Rousset, Maladie veineuse thromboembolique et cancer. La Revue de médecine interne, pp.313-322, 2006.

P. Tourreau, S. Fattorutto, M. Bonnin, P. Mazoyer, E. Raphael et al., Etude des effets directs et indirects de l'erythropoïétine dans un modèle

P. Rousselot, Lénograstime (rHuG-CSF glycosylé) ou filgrastime (r-metHuG-CSF) : un choix difficile ?

J. Sauvanet, Mircera?? : le premier activateur connu de l?????rythropo????se ?? injection mensuelle, M??decine des Maladies M??taboliques, vol.2, issue.6, p.661, 2008.
DOI : 10.1016/S1957-2557(08)74948-4

C. Sauve, M. Boffa, and G. Meyer, Maladie thromboembolique veineuse et cancer, La Revue de M??decine Interne, vol.21, issue.3, pp.266-277, 2000.
DOI : 10.1016/S0248-8663(00)80046-6

M. Scrobohaci, Anticorps antiphospholipides et cancer, Pathologie Biologie, vol.56, issue.4, pp.245-250, 2008.
DOI : 10.1016/j.patbio.2008.02.012

D. Shasha, The negative impact of anemia on radiotherapy and chemoradiation outcomes, Seminars in Hematology, vol.38, pp.8-15, 2001.
DOI : 10.1016/S0037-1963(01)90125-8

P. Stohlawetz, L. Dzirlo, N. Hergovich, E. Lackner, C. Mensik et al., Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans, Blood, vol.95, issue.9, pp.2983-2989, 2000.

M. Tijssen, E. Van-der-schoot, C. Voermans, and J. Zwaginga, Clinical approaches involving Thrombopoietin to schorten the period of thrombocytopenia after high-dose chemotherapy. Transfusion medicine reviews, pp.283-293, 2006.

P. Vaupel and A. Mayer, Hypoxia and anemia: effects on tumor biology and treatment resistance, Transfusion Clinique et Biologique, vol.12, issue.1, pp.5-10, 2005.
DOI : 10.1016/j.tracli.2004.11.005

S. Wagner, E. Ciobanu, L. Federici, J. Zimmer, C. Ronde-oustau et al., De nouvelles perspectives dans le traitement du purpura thrombopénique : les agonistes du récepteur de la thrombopoïétine, Mt, vol.14, pp.96-104, 2008.

T. Wakefield, R. Strieter, M. Prince, L. Downing, and L. Greenfield, Pathogenesis of venous thrombosis: a new insight, Cardiovascular Surgery, vol.5, issue.1, pp.6-15, 1997.
DOI : 10.1016/S0967-2109(96)00083-X

T. Wang, Z. Wang, and R. Yang, Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura, Critical Reviews in Oncology/Hematology, vol.77, issue.3, 2010.
DOI : 10.1016/j.critrevonc.2010.03.001

Y. Yasuda, Y. Fujita, T. Matsuo, S. Koinuma, S. Hara et al., Erythropoietin regulates tumour growth of human malignancies, Carcinogenesis, vol.24, issue.6, pp.1021-1029, 2003.
DOI : 10.1093/carcin/bgg060

M. Zandecki and . Physiologie-de-la-mégaryopoïèse, Cours d'hématologie biologique, Faculté de Médecine d'Angers, 2006.

Y. Zermati, Régulation de l'érythropoïèse : applications physiopathologiques en néphrologie. Flammarion médecine sciences Actualités néphrologiques, pp.117-138, 2003.